In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.
Roy S. Herbst, MD, PhD
With the new direction in research and clinical trials, treating patients who most benefit from treatment with minimal toxicity will continue to be the mainstay of personalized cancer therapy.
This special “annual highlights” supplement to Oncology News International is a
compilation of major advances in the management of lung cancer during 2003, as
reported in ONI. Guest editor Dr. Roy Herbst comments on the reports included
herein and discusses advances in the clinical management of lung cancer, with a
focus on developments in targeted therapy, new combinations, adjuvant therapy,
induction therapy, and what to watch for in 2004.